Cargando…

The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma

BACKGROUND: An increasing number of studies support cancer stem cells as the reason for chemoresistance to sorafenib therapy in hepatocellular carcinoma (HCC), but the mechanism is still unclear. In this study, the mechanism of sorafenib resistance in cancer stem cells was examined by in vitro exper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Chiung-Chi, Chao, Wei-Ting, Liao, Chen-Chun, Shih, Jing-Hao, Lai, Yih-Shyong, Hsu, Yung-Hsiang, Liu, Yi-Hsiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783114/ https://www.ncbi.nlm.nih.gov/pubmed/31632072 http://dx.doi.org/10.2147/OTT.S217468

Ejemplares similares

Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment
por: Cheng, Chiung-Chi, et al.
Publicado: (2017)

The Prognostic Value of Cytokeratin and Sal-Like Protein 4 Expression in Hepatocellular Carcinoma and Intra-Hepatic Cholangiocarcinoma in Taiwan
por: Lai, Yih-Shyong, et al.
Publicado: (2018)

Transient knockdown-mediated deficiency in plectin alters hepatocellular motility in association with activated FAK and Rac1-GTPase
por: Cheng, Chiung-Chi, et al.
Publicado: (2015)

Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma
por: Perng, Pang-Shuo, et al.
Publicado: (2022)

Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
por: Liang, Kung-Hao, et al.
Publicado: (2021)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
por: Hsu, Tung-Wei, et al.
Publicado: (2023)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure
por: Cheng, Tsung-Yi, et al.
Publicado: (2020)

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
por: Hsu, Chih-Hung, et al.
Publicado: (2014)

A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma
por: Lin, Chih-Lang, et al.
Publicado: (2023)

Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib
por: Hsieh, Ming-Han, et al.
Publicado: (2020)

Physical Gold Nanoparticle-Decorated Polyethylene Glycol-Hydroxyapatite Composites Guide Osteogenesis and Angiogenesis of Mesenchymal Stem Cells
por: Shen, Chiung-Chyi, et al.
Publicado: (2021)

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2019)

A primary paraganglioma of the liver mimicking hepatocellular carcinoma
por: Lin, Chia-Shuen, et al.
Publicado: (2019)

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma
por: Kuczynski, Elizabeth A., et al.
Publicado: (2016)

Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2020)

Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
por: Lee, I-Cheng, et al.
Publicado: (2015)

Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma
por: Suk, Fat-Moon, et al.
Publicado: (2019)

Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma
por: Liao, Yi-Jen, et al.
Publicado: (2020)

Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
por: Kim, Bo Hyun, et al.
Publicado: (2019)

OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53
por: Omar, Hany A., et al.
Publicado: (2016)

Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma
por: Tsai, Hung-Wen, et al.
Publicado: (2023)

Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
por: Chen, Yunching, et al.
Publicado: (2017)

Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma
por: Wu, Wei-De, et al.
Publicado: (2018)

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
por: Chen, San-Chi, et al.
Publicado: (2022)

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling
por: Zhou, Xin, et al.
Publicado: (2022)

Fe(3+)-binding transferrin nanovesicles encapsulating sorafenib induce ferroptosis in hepatocellular carcinoma
por: Xiao, Youmei, et al.
Publicado: (2023)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
por: Peng, Syue-Wei, et al.
Publicado: (2023)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial
por: Lee, Teng-Yu, et al.
Publicado: (2017)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma
por: Zheng, Ruiqi, et al.
Publicado: (2023)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_36gj630b9o92pl5mv5nvpgos72